ZA201901536B - Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders - Google Patents
Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disordersInfo
- Publication number
- ZA201901536B ZA201901536B ZA2019/01536A ZA201901536A ZA201901536B ZA 201901536 B ZA201901536 B ZA 201901536B ZA 2019/01536 A ZA2019/01536 A ZA 2019/01536A ZA 201901536 A ZA201901536 A ZA 201901536A ZA 201901536 B ZA201901536 B ZA 201901536B
- Authority
- ZA
- South Africa
- Prior art keywords
- neurodegenerative disorders
- methods
- nicotinamide riboside
- pterostilbene
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title abstract 4
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 4
- 235000020956 nicotinamide riboside Nutrition 0.000 title abstract 4
- 239000011618 nicotinamide riboside Substances 0.000 title abstract 4
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 title abstract 4
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378053P | 2016-08-22 | 2016-08-22 | |
| PCT/US2017/047979 WO2018039207A1 (en) | 2016-08-22 | 2017-08-22 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201901536B true ZA201901536B (en) | 2024-06-26 |
Family
ID=61246253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/01536A ZA201901536B (en) | 2016-08-22 | 2019-03-12 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11260069B2 (enExample) |
| EP (1) | EP3500267A4 (enExample) |
| JP (1) | JP7132907B2 (enExample) |
| KR (1) | KR20190046895A (enExample) |
| CN (2) | CN109982706A (enExample) |
| AU (1) | AU2017316614B2 (enExample) |
| BR (1) | BR112019003579A2 (enExample) |
| CA (1) | CA3034673A1 (enExample) |
| MX (1) | MX2019002211A (enExample) |
| RU (1) | RU2019108100A (enExample) |
| WO (1) | WO2018039207A1 (enExample) |
| ZA (1) | ZA201901536B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7132907B2 (ja) | 2016-08-22 | 2022-09-07 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法 |
| EP3624808A4 (en) * | 2017-05-18 | 2021-03-03 | Elysium Health, Inc. | PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| CA3108015A1 (en) | 2017-07-28 | 2019-01-31 | Centers For Age Control, Inc. | Compositions and methods for preventing and reversing aspects of aging |
| CN112955150A (zh) * | 2018-10-19 | 2021-06-11 | 达萨玛治疗公司 | 与nad+或nad+前体组合的sarm1抑制剂 |
| WO2020102326A1 (en) * | 2018-11-13 | 2020-05-22 | Elysium Health, Inc | Methods for determining and increasing nad levels |
| WO2020131578A2 (en) | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| JP7580380B2 (ja) * | 2019-02-26 | 2024-11-11 | ウニベルシタット デ バレンシア―エストゥディ ジェネラル | 運動ニューロン疾患を処置するための方法及び組成物 |
| CN110812365A (zh) * | 2019-11-07 | 2020-02-21 | 明特奇点医疗科技（北京）有限公司 | 一种组合物及其制备方法与制剂 |
| CN111838669B (zh) * | 2020-08-07 | 2022-11-29 | 四川大学华西医院 | 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途 |
| EP4029496A1 (en) * | 2021-01-18 | 2022-07-20 | Universitat de València | Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases |
| EP4079311B1 (en) | 2021-04-20 | 2025-10-01 | Nuvamid SA | Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism |
| WO2022269064A1 (en) * | 2021-06-24 | 2022-12-29 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| DK4284387T3 (da) * | 2021-06-24 | 2024-09-02 | Vestlandets Innovasjonsselskap As Vis | Nad-forstærkelsesterapi til parkinsons sygdom |
| CN117615768A (zh) * | 2021-06-24 | 2024-02-27 | 韦斯特兰德特斯创新股份公司 | 用于帕金森病的nad增效疗法 |
| CN118176006A (zh) * | 2021-10-27 | 2024-06-11 | 益力舒健康公司 | 治疗更年期综合征的方法 |
| EP4727544A2 (en) | 2023-06-14 | 2026-04-22 | Chromadex Inc. | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof |
| CN116807985A (zh) * | 2023-06-20 | 2023-09-29 | 风火轮(上海)生物科技有限公司 | 一种烟酰胺核糖组合物及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964627B (zh) | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20090069444A1 (en) | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
| US20090163580A1 (en) * | 2007-12-24 | 2009-06-25 | Natrol, Inc. | Anti-aging composition containing resveratrol and method of administration |
| WO2010095926A1 (en) * | 2009-02-20 | 2010-08-26 | N.V. Nutricia | Use of reveratrol for preserving cognitive functioning |
| EP2445488B1 (en) | 2009-06-22 | 2020-03-18 | Indus Biotech Private Limited | Process for obtaining purified pterostilbene and methods of use thereof |
| WO2011011721A2 (en) | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| US9439875B2 (en) | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
| EP2574339A1 (de) * | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
| US20130149277A1 (en) | 2011-12-13 | 2013-06-13 | Cliffstar Llc | Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders |
| US20130296440A1 (en) | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| JP6509844B2 (ja) * | 2013-10-30 | 2019-05-08 | クロマデックス, インコーポレイテッドChromaDex, Inc. | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| WO2016122832A1 (en) * | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries |
| WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| JP7132907B2 (ja) | 2016-08-22 | 2022-09-07 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法 |
-
2017
- 2017-08-22 JP JP2019510843A patent/JP7132907B2/ja active Active
- 2017-08-22 MX MX2019002211A patent/MX2019002211A/es unknown
- 2017-08-22 BR BR112019003579-6A patent/BR112019003579A2/pt not_active Application Discontinuation
- 2017-08-22 CN CN201780064669.9A patent/CN109982706A/zh active Pending
- 2017-08-22 US US16/327,651 patent/US11260069B2/en active Active
- 2017-08-22 CN CN202211250881.3A patent/CN115645432A/zh active Pending
- 2017-08-22 RU RU2019108100A patent/RU2019108100A/ru not_active Application Discontinuation
- 2017-08-22 WO PCT/US2017/047979 patent/WO2018039207A1/en not_active Ceased
- 2017-08-22 CA CA3034673A patent/CA3034673A1/en active Pending
- 2017-08-22 EP EP17844270.3A patent/EP3500267A4/en not_active Withdrawn
- 2017-08-22 KR KR1020197008293A patent/KR20190046895A/ko not_active Ceased
- 2017-08-22 AU AU2017316614A patent/AU2017316614B2/en active Active
-
2019
- 2019-03-12 ZA ZA2019/01536A patent/ZA201901536B/en unknown
-
2022
- 2022-01-21 US US17/580,999 patent/US11998561B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017316614A1 (en) | 2019-03-21 |
| EP3500267A4 (en) | 2020-03-18 |
| CN109982706A (zh) | 2019-07-05 |
| MX2019002211A (es) | 2019-10-30 |
| RU2019108100A3 (enExample) | 2020-11-27 |
| US20220143055A1 (en) | 2022-05-12 |
| BR112019003579A2 (pt) | 2019-05-21 |
| US11998561B2 (en) | 2024-06-04 |
| US11260069B2 (en) | 2022-03-01 |
| RU2019108100A (ru) | 2020-09-22 |
| US20190201426A1 (en) | 2019-07-04 |
| JP7132907B2 (ja) | 2022-09-07 |
| EP3500267A1 (en) | 2019-06-26 |
| JP2019524856A (ja) | 2019-09-05 |
| CN115645432A (zh) | 2023-01-31 |
| WO2018039207A1 (en) | 2018-03-01 |
| CA3034673A1 (en) | 2018-03-01 |
| AU2017316614B2 (en) | 2023-06-15 |
| KR20190046895A (ko) | 2019-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002211A (es) | Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos. | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| PH12019502793A1 (en) | Aadc polynucleotides for the treatment of parkinson`s disease | |
| ZA201800056B (en) | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders | |
| MX2018011114A (es) | Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías. | |
| EP4707410A3 (en) | Regulate gut microbiota to treat neurodegenerative disorders | |
| PH12017500746B1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| MX2017005834A (es) | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| IL277182A (en) | Compositions and methods for treating Parkinson's disease | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| TW201613636A (en) | Methods of treating Alzheimer's Disease | |
| MX2015017253A (es) | Composiciones y metodos para tratar trastornos metabolicos. | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| PT3302454T (pt) | Composições para utilização no tratamento da doença de parkinson e distúrbios associados | |
| EP3261446A4 (en) | Methods and compositions for the treatment or prevention of parkinson's disease | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| MX2018005312A (es) | Composiciones y metodos para el tratamiento de la homocistinuria. | |
| MX2025015454A (es) | Formulaciones/composiciones que comprenden ibrutinib | |
| EP3554496A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | |
| ZA201802606B (en) | Compositions for dental varnishes and methods of making and using same | |
| IL265656A (en) | Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease |